Literature DB >> 23635505

[Summary of the NHG practice guideline 'Lower urinary tract symptoms in men'].

Marco H Blanker1, M A Rien Klomp, Maureen van den Donk, Wouter K van der Heide, Wim Opstelten, Jako S Burgers.   

Abstract

In general practice, lower urinary tract symptoms (LUTS) in men are usually not attributable to specific disorders. Prostate cancer is rarely the cause of LUTS. Education, counselling, and non-pharmaceutical advice form the basis for treatment of LUTS. Only when these measures do not relieve the patient's symptoms sufficiently, drug therapy could be considered. Alpha-blockers are the drugs of first choice and are also recommended when transurethral catheterization is needed for acute urinary retention. The effect of medication on LUTS is limited and largely based on placebo effect. The effectiveness of prostate cancer screening is a subject of debate; therefore patients asking for a PSA test should be informed about the benefits and harms of measuring PSA before having a test. A PSA value > 4 ng/ml, or abnormal results on digital rectal examination should prompt further diagnostic evaluation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23635505

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  9 in total

1.  What Do Men with Lower Urinary Tract Symptoms Expect from a Urologist in Secondary Care?

Authors:  Pim Brandenbarg; Puk Rooijers; Martijn G Steffens; Michael R van Balken; Henk-Jan Mulder; Marco H Blanker
Journal:  Patient Prefer Adherence       Date:  2020-08-19       Impact factor: 2.711

2.  Continuation rates of alpha-blockers mono-therapy in adult men, prescribed by urologists or general practitioners: a pharmacy-based study.

Authors:  Ilse M J Hordijk; Martijn G Steffens; Eelko Hak; Marco H Blanker
Journal:  World J Urol       Date:  2018-11-13       Impact factor: 4.226

3.  Discontinuation of alpha-blocker therapy in men with lower urinary tract symptoms: a systematic review and meta-analysis.

Authors:  Henk van der Worp; Petra Jellema; Ilse Hordijk; Yvonne Lisman-van Leeuwen; Lisa Korteschiel; Martijn G Steffens; Marco H Blanker
Journal:  BMJ Open       Date:  2019-11-07       Impact factor: 2.692

4.  Determining the minimal important differences in the International Prostate Symptom Score and Overactive Bladder Questionnaire: results from an observational cohort study in Dutch primary care.

Authors:  Marco H Blanker; Harma Johanna Alma; Tahira Sakina Devji; Marjan Roelofs; Martijn G Steffens; Henk van der Worp
Journal:  BMJ Open       Date:  2019-12-23       Impact factor: 2.692

5.  Development of an online personalized self-management intervention for men with uncomplicated LUTS.

Authors:  Marco H Blanker; Pim Brandenbarg; Bart G C Slijkhuis; Martijn G Steffens; Michael R van Balken; Petra Jellema
Journal:  Neurourol Urodyn       Date:  2019-05-20       Impact factor: 2.696

6.  General practitioners' approaches to prostate-specific antigen testing in the north-east of the Netherlands.

Authors:  Sanny Kappen; Lisa Koops; Verena Jürgens; Michael H Freitag; Marco H Blanker; Antje Timmer; Geertruida H de Bock
Journal:  BMC Fam Pract       Date:  2020-12-17       Impact factor: 2.497

7.  Differences in Prostate Cancer Incidence and Mortality in Lower Saxony (Germany) and Groningen Province (Netherlands): Potential Impact of Prostate-Specific Antigen Testing.

Authors:  Sanny Kappen; Geertruida H de Bock; Eunice Sirri; Claudia Vohmann; Joachim Kieschke; Alexander Winter
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 6.244

8.  Effectiveness of a newly developed online self-management program for male patients with uncomplicated lower urinary tract symptoms.

Authors:  Marco H Blanker; Anja Admiraal; Pim Brandenbarg; Martijn G Steffens; Michael R van Balken; Henk-Jan Mulder; Henk van der Worp
Journal:  Neurourol Urodyn       Date:  2019-08-06       Impact factor: 2.696

9.  Attitudes Toward and Use of Prostate-Specific Antigen Testing Among Urologists and General Practitioners in Germany: A Survey.

Authors:  Sanny Kappen; Verena Jürgens; Michael H Freitag; Alexander Winter
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.